Compare Corsair Gaming Inc (CRSR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corsair Gaming Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Corsair Gaming Inc trades at $13.45 (market cap $1.42B), while Vertex Pharmaceuticals Incorporated trades at $510.21 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 89.8× Corsair Gaming Inc's market cap, and Corsair Gaming Inc is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Corsair Gaming Inc for 25 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| CRSR | VRTX | |
|---|---|---|
Market Cap | $1.42B | $127.55B |
Volume | 1,160,938 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $14.35 | $557.96 |
52-Week Low | $4.58 | $407.37 |
Typical Hold Time | 25 Days | 120 Days |
Enterprise Value | $1.41B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corsair Gaming (CRSR) trades at $13.505, down 0.63% on the day, with a bullish technical signal and recent earnings beats driving positive momentum. The stock shows improving fundamentals with a projected net income margin of 2.53% for 2026, though current valuation metrics like a P/E of 42.23 appear elevated. Recent product launches and strategic acquisitions highlight growth initiatives in the gaming and creator segments.
The outlook is cautiously optimistic, supported by analyst buy ratings and strong cash flow projections for 2026. Key risks include competitive pressures and reliance on consumer discretionary spending, but institutional interest and earnings outperformance provide a foundation for potential upside if execution continues.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Corsair Gaming Inc
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
